Skip to content
0727
InsightsAcademyCasesEventsSign in
中文/EN
Cases/Syneos Health
← Back to cases
← Previous19 / 127Next →

Syneos Health

Clinical trial site selection, forecasting and document workflow
Microsoft Clinical research services Embedded deployment ⚙ Technical reference Deep case | Key delivery chain is substantially documented Evidence level A In production / expanding
A Evidence level
Syneos Health reduces time for clinical trial site activation
Publisher: Microsoft · Case of the official customer of the manufacturer · Direct sources at the case level
Claim origin: Microsoft & Client Disclosure · Independent verification: No · Accessed: 2026-09-19
Evidence level measures whether a source can be located and reviewed; it does not mean vendor-reported claims were independently audited.
Deep case | Key delivery chain is substantially documented 12 / 12
Business context2 / 2
Transformation workflow2 / 2
Technical workflow2 / 2
Human roles & governance2 / 2
Measured outcomes2 / 2
Source traceability2 / 2
All six dimensions meet the current completeness threshold.
Syneos Health combines unified data platforms, forecasting models and generation AIs into clinical trial site selection and risk management, reducing candidate generation and retaining final decision-making by clinical specialists.
Business problem

Syneos Health runs more than 500 clinical trials simultaneously, and test sites require manual collection and comparison of a large number of sites, subjects and historical data, often for months; the team also handles forecasts, files and client landscape discussions.

Solution

The company builds a unified analysis platform on data assets that have been relocated to Azure, using Data Lake, Databricks, machine learning, data quality capabilities and Azure OpenAI to develop generative AI applications; the system masters serve as a list of candidate sites, then support a gradual screening process, and test the extension risk through predictive models, allowing staff to demonstrate different options in real time.

Technical architecture & production workflow
Step 01
Clinical, site, subject and operation data
→
Step 02
Azure Data Lake Harmonized Storage and Data Quality
→
Step 03
Azure Databricks conversion and analysis
→
Step 04
Traditional machine learning predicts test risks
→
Step 05
Azure OpenAI to generate candidate lists and scenario analysis
→
Step 06
Clinical specialist clearance, selection and risk disposal
Key technology & infrastructure components
Azure Data Lake StorageAzure DatabricksAzure OpenAIMLOpsForecast modelsExpert review
Human roles & accountability

AI generates candidate sites, predicts risks and supports scenario analysis; clinical operations and medical specialists review site qualifications, risks and compliance requirements, and final test design and patient safety responsibilities remain with professional teams.

FDE delivery actions
  • Modern data platforms before entering the generative AI scene
  • Select the first end-to-end process with the site
  • Connect prediction models to generate interactions
  • Bringing clinical teams into real-time ICP in client meetings
  • Validate results using candidate list duration and active cycle
Reusable delivery patterns
  • Generating AI should reuse existing data and predictive capabilities of the enterprise
  • Clinical scenes need to separate candidate generation from final eligibility decisions
  • Project cycle, duration of local processing and final business cycle to be measured separately
  • Risk alerts are valuable only if they enter the team disposal process.
Business outcomes & delivery results

The Microsoft case states that the platform was deployed over a nine-month period and that the initial site list could be generated from 24 to 48 hours, with subsequent screening reduced from several months to several weeks; and the 2024 site activation cycle reduced by approximately 10 per cent.

Evidence boundaries & verification notes
  • The 24-48 hours, weeks of screening and 10 per cent reduction in the activation cycle of the site list are indicators at different process levels.
  • The public page does not disclose test types, samples and comparison methods.
Primary source: Syneos Health reduces time for clinical trial site activation ↗
Traceable does not mean independently audited
Open primary public source
0727.ai · Trusted agents, built together.Case research: FDE-case-library ↗ · MIT